Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Evaluations and Price Predictions for Teleflex NYSE TFX

Elaine Mendonca by Elaine Mendonca
January 12, 2024
in Breaking News
0
Healthcare Services Stock Exchange
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

As of January 12, 2024, analysts have shared their evaluations and price predictions for Teleflex (NYSE: TFX). These assessments offer valuable insights into the company’s potential performance. The average projected price for Teleflex over the next 12 months is $250.7, with a high estimate of $285.00 and a low estimate of $221.00. This indicates a positive trend compared to the previous average price target of $233.78.

Taking into account 2 buy ratings, 4 hold ratings, and 0 sell ratings, the consensus rating for Teleflex is considered a Moderate Buy. Analysts have recently made adjustments to their ratings and price targets for Teleflex, demonstrating their ongoing assessment of the company’s prospects. They have raised, maintained, and even lowered their ratings and price targets accordingly.

The average 12-month price prediction for Teleflex stands at $264.90, with a high price target of $293.00 and a low price target of $225.00. These figures collectively provide a comprehensive overview of the current analyst projections for Teleflex.

TFX Stock: Strong Performance and Positive Price Momentum on January 12, 2024

TFX stock showcased a strong performance on January 12, 2024, trading near the top of its 52-week range and above its 200-day simple moving average. The stock closed at $249.15, indicating positive price momentum. The stock witnessed an increase of $0.81 since the market last closed, representing a rise of 0.33%. The stock’s price remained unchanged in after-hours trading, indicating stability. Trading near the top of its 52-week range suggests consistent performance over the past year. The stock being above its 200-day simple moving average suggests an uptrend. However, investors should conduct thorough research and analysis before making any investment decisions.

Tags: TFX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Alternative Energy Markets and money (1)

Analyst Reiterates Positive Stance on Chesapeake Energy with Adjusted Price Target

Entertainment Markets and money (1)

Live Nation Entertainment Poised for Remarkable Growth in Live Events and Concerts

Technology Artificial intelligence Markets and money

The Battle for DocuSign A HighStakes Acquisition Battle

Recommended

EV

Analyst Reaffirms Buy Rating and Raises Price Target for Tradeweb Markets

2 years ago
Nerdwallet Stock

Why Nerdwallet Stock Remains a Top Analyst Pick Despite Revenue Shortfall

3 months ago
MP Materials Stock

Diverging Investment Patterns Emerge in MP Materials Stock

2 months ago
ABM Industries Stock

ABM Industries Stock: Can New Board Leadership Spark a Turnaround?

6 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Trending

Illumina Stock
Analysis

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

by Felix Baarz
November 6, 2025
0

A significant regulatory shift from China has injected fresh momentum into Illumina's stock, as the country removes...

Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach
  • DuPont Faces Critical Test as Quarterly Results Loom

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com